INDIGO is a research and innovation Project jointly funded by the European Commission, as part of the Horizon 2020 research and innovation program, and India’s Department of Biotechnology. The interdisciplinary Consortium consists of 16 partners from India, the European Union and the United States.

This 5-year program contributes to Sustainable Development Goal 3, to ensure health and well-being, at every stage of life, by aiming at the development of an improved seasonal and pandemic vaccines.

For the seasonal vaccine, a reduced dose of existing vaccines will be combined with a new adjuvant to reduce the price of the vaccine while also improving the efficacy, with the goal to increase accessibility of the vaccine in India and other regions of the world regarded as low- to middle- income countries. With respect to the pandemic vaccine, the goal is to be better prepared for future pandemics by improving efficacy, with a focus on the removal of regulatory T cell epitopes, new adjuvants, and an alternative route of administration.